Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Starting soon · Phase 4

Conditions studied: Atrial Fibrillation (AF)

In brief

To evaluate whether pre-treatment with semaglutide is superior to standard care in improving freedom from atrial fibrillation (AF) at 12 months following catheter ablation in patients with obesity and symptomatic AF undergoing first-time ablation.

Key facts

Study ID
NCT07389941
Run by
University of Luebeck
People needed
240
Starts
2026-10-01
Expected to finish
2029-04-01
Last updated by the study team
2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.